^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA replication inhibitor

    Related drugs:
    Apply
    IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (IMGN632-0802) (NCT04086264)
    Phase 1/2
    AbbVie
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/06/2019
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)
    Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (A041703) (NCT03739814)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/08/2019
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    ABL1 • BCR • CD22
    |
    CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (NCT03839446)
    Phase 2
    Robert Redner, MD
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    02/28/2019
    Primary completion :
    02/02/2023
    Completion :
    12/22/2024
    CD33
    |
    CD33 expression
    |
    etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone
    A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML (AGORA-1) (NCT05199051)
    Phase 2
    Centre Antoine Lacassagne
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/03/2023
    Primary completion :
    03/15/2027
    Completion :
    03/15/2027
    FLT3 • CD33
    |
    FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive
    |
    cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)
    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (NCT04293562)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/21/2020
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    FLT3
    |
    Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane
    Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (AALL1621) (NCT02981628)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    06/19/2017
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    KMT2A • CD22
    |
    MLL rearrangement • CD22 expression
    |
    cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG) (NCT05716009)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/20/2023
    Primary completion :
    12/25/2027
    Completion :
    12/25/2028
    CD33 • IL3RA
    |
    CD123 expression
    |
    Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)
    Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (NCT04915612)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    05/21/2021
    Primary completion :
    01/30/2025
    Completion :
    01/30/2025
    CD33
    |
    CD33 positive
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCI-2018-01812) (NCT03672539)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/07/2018
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    CD33
    |
    CD33 positive
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML (NCT05558124)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/16/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    CD33
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05672251)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/02/2024
    Primary completion :
    04/22/2025
    Completion :
    04/22/2025
    CD20
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (SWOG-S0703) (NCT00658814)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    12/01/2008
    Primary completion :
    06/01/2013
    Completion :
    03/07/2025
    CD4
    |
    azacitidine • Mylotarg (gemtuzumab ozogamicin)